DMT1 is a key protein regulating iron balance, and DMT1 inhibitors have been reported to selectively target CSCs in primary cancer cells and circulating cancer cells, causing ferroptosis in breast cancer CSCs and reversing multidrug resistance through lysosomal iron accumulation and ROS production.191. Here, SLC11A2 is linked to breast cancer.